Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T ... Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs. Mehr anzeigen
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for...
Tab-cel® U.S. BLA On-Track With PDUFA Target Action Date of January 15, 2025 First Patient Dosed for ATA3219 Non-Hodgkin’s Lymphoma Study; Initial Clinical Data Expected Q1 2025 ATA3219 Lupus...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 4.16 | 41.1881188119 | 10.1 | 14.9299 | 10.02 | 192273 | 12.68656371 | CS |
| 4 | 4.83 | 51.2195121951 | 9.43 | 14.9299 | 8.24 | 139913 | 10.7739628 | CS |
| 12 | 7 | 96.4187327824 | 7.26 | 14.9299 | 6.65 | 151430 | 9.21746217 | CS |
| 26 | -0.74 | -4.93333333333 | 15 | 18.25 | 6.5 | 347623 | 12.53532886 | CS |
| 52 | 5.075 | 55.2531301034 | 9.185 | 39.5 | 6.5 | 1720958 | 17.17076468 | CS |
| 156 | -426.74 | -96.7664399093 | 441 | 471.25 | 4.965 | 1676148 | 75.90821878 | CS |
| 260 | -318.74 | -95.7177177177 | 333 | 705 | 4.965 | 1355493 | 151.507654 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
